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Abstract
Background: Prior to clinical trials of new TB drugs or therapeutic vaccines, it is necessary to develop
monitoring tools to predict treatment outcomes in TB patients. Urine interferon gamma inducible protein
10 (IP-10) is a potential biomarker of treatment response in chronic hepatitis C virus infection and lung
diseases, including tuberculosis. In this study, we assessed IP-10 levels in urine samples from patients with
active TB at diagnosis, during treatment, and at completion, and compared these with levels in serum
samples collected in parallel from matched patients to determine whether urine IP-10 can be used to
monitor treatment response in patients with active TB.
Methods: IP-10 was measured using enzyme-linked immunosorbent assays in urine and serum samples
collected concomitantly from 23 patients with active TB and 21 healthy adults (44 total individuals). The
Mann-Whitney U test and Wilcoxon matched-pairs signed rank test were used for comparisons among
healthy controls and patients at three time points, and LOESS regression was used for longitudinal data.
Results: The levels of IP-10 in urine increased significantly after 2 months of treatment (P = 0.0163), but
decreased by the completion of treatment (P = 0.0035). Serum IP-10 levels exhibited a similar trend, but
did not increase significantly after 2 months of treatment in patients with active TB.
Conclusions: Unstimulated IP-10 in urine can be used as a biomarker to monitor treatment response in
patients with active pulmonary TB.
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Background
Tuberculosis (TB) remains a major infectious cause of
mortality and morbidity, with approximately 8.6 million
new cases and 1.3 million deaths per year [1]. In addition,
there is concern over increasing rates of disease recur-
rence (including relapse and reinfection) after anti-TB
drug therapy and an increasing trend of multidrug- and
extensively drug-resistant (M/XDR) TB worldwide.
Progress has been made in the control of tuberculosis, as
advocated by the World Health Organization (WHO) [2].
For the development of novel vaccines and drugs
against TB, a reliable surrogate marker of risk and pro-
tection against TB is essential. In particular, prior to
clinical trials of new therapeutic vaccines to prevent TB
recurrence and to shorten the duration of therapy, ef-
fective monitoring tools are needed to measure treat-
ment responses to standard drug therapies in parallel
with therapeutic vaccinations [3, 4].
Generally, sputum culture conversion after 2 months
of anti-TB drug treatment has been used as a predict-
ive indicator of drug treatment response in patients
[5–9]. However, culture methods are not applicable in
patients with extrapulmonary TB and culture-negative
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pulmonary TB, and laboratories capable of sputum
culture are often lacking in resource-limited settings
[10–12]. To accommodate these shortcomings, efforts
have been made to identify an alternative biomarker
for anti-TB treatment efficacy [4, 13, 14].
Interferon gamma (IFN-γ)-inducible protein (IP-10) is
a pro-inflammatory chemokine secreted by antigen-
presenting cells that transport activated T lymphocytes
to sites of inflammation [15, 16]. IP-10 levels were found
to be higher in the unstimulated serum, plasma, and
urine of patients with active TB than those in subjects
without active TB, and IP-10 levels decrease significantly
after the completion of anti-TB treatment [15, 17–20].
Among all types of clinical specimens in which IP-10
has been detected, urine specimens are the most con-
venient and non-invasive; specimens can be obtained
from children and elderly patients, even in resource-
limited settings, as these samples do not require special
equipment or skilful medical personnel for collection. In
addition, urine specimens present lower handling risks
compared to other specimens, such as blood, sputum,
and microbial isolates from patients [20].
The aim of this study was to test the hypothesis
that levels of urine IP-10 change over the course of
anti-TB drug therapy in patients with active TB from
South Korea, an area with an intermediate burden of
TB and low burden of human immunodeficiency virus
infection and acquired immune deficiency syndrome
(HIV/AIDS).
Methods
Study population and setting
Clinical information and specimens were collected from
participants enrolled in two clinical studies from
November 2010 to March 2012 and from May 2015 to
June 2016. The Institutional Ethics Committee of Yonsei
University Severance Hospital approved this study
(approval #4-2010-0527 and #4-2014-1108). All study
participants provided written informed consent to pro-
vide specimens for the identification of TB biomarkers.
Study participants were classified as follows.
1) Active pulmonary TB patients (aged 20 years and
over): Patients with active pulmonary TB were
diagnosed based on culture and/or pathology. Cases
of clinical active pulmonary TB, which
was defined as negative mycobacterial culture
findings, but favourable clinical and radiological
responses to anti-TB medication, were also
included. Patients were sub-divided into the
following three groups based on risk factors for re-
lapse, including the presence of (i) a cavity
lesion on a chest X-ray or chest CT and (ii) a
positive sputum culture after 2 months of
anti-TB treatment as follows:
 Low-risk group: TB patients who had neither risk
factor (i) nor (ii);
 Moderate group: TB patients who had either risk
factor (i) or (ii);
 High-risk group: TB patients who had both risk
factors (i) and (ii).
2) Healthy controls (aged 20 years and over): Healthy
controls fulfilled the following inclusion criteria: (i)
no history of tuberculosis, (ii) no suggestive
symptoms of tuberculosis, (iii) no recent contact
with patients with infectious tuberculosis, and (iv)
negative results according to the QuantiFERON®-TB
Gold In-Tube Test (QFT-GIT).
None of the participants exhibited HIV infection; a
chronic comorbidity, such as diabetes mellitus,
chronic renal failure, malignant tumour, or chronic
liver disease; immunosuppressive status; or acute
infections.
IFN-γ measurement
A QFT-GIT assay was conducted for all patients before
treatment (0 months, T0), at 2 months (T2), and at 6–
9 months after the treatment was completed (T6).
The QFT-GIT assay (Qiagen, Hilden, Germany) was
performed according to the manufacturer’s instruc-
tions. Briefly, 1 ml of whole blood was collected in
each of three tubes pre-coated with Mycobacterium
tuberculosis-specific peptides (ESAT-6, CFP-10, and
TB7.7) or mitogen (positive control) and incubated
for 16–24 h at 37 °C. For negative controls, whole
blood was placed in tubes that were not pre-coated.
The plasma supernatant was harvested by centrifuga-
tion at 3000×g for 15 min and stored at − 80 °C. The
level of IFN-γ was determined using the QFT
Enzyme-linked Immunosorbent Assay (ELISA) Kit.
The results were interpreted using QFT-GIT software
version 2.62, provided by the manufacturer.
IP-10 measurement
Serum and urine samples were collected to measure ser-
ial IP-10 levels from all patients at T0, T2, and T6. IP-10
levels in urine and serum were concomitantly measured
in duplicate using a commercial IP-10 ELISA Kit (R&D
Systems, Minneapolis, MN, USA) in accordance with
the manufacturer’s instructions. The test results were
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interpreted using SoftMax version 5.4.1 (Molecular De-
vices, LLC, Sunnyvale, CA, USA). In addition, using the
test results available from routine hospital analyses, the
urine IP-10 level (in pg/ml) was normalized against the
serum creatinine level (in mg/ml) for each patient at
each visit.
Statistical analysis
All statistical analyses were performed using GraphPad
Prism 6 software (GraphPad Software, La Jolla, CA,
USA) and IBM SPSS software version 21.0 (IBM Corp.,
Armonk, NY, USA). Medians and interquartile range
(IQR) were measured for continuous variables. The
Mann–Whitney U-test and Wilcoxon matched-pairs
signed rank test were used for comparisons among study
groups and pairwise comparisons. A longitudinal
smoothed trend line for the data (not based on any dis-
tributional assumption) was estimated using a nonpara-
metric method called LOESS (locally weighted
scatterplot smoothing). A 95% confidence limit was esti-
mated, and similarity patterns by risk group were graph-
ically examined. All P-values were two-sided, and P < 0.
05 was considered statistically significant.
Results
Characteristics of study participants
We enrolled 23 patients with active TB and 21 healthy
controls. The patients with active TB had a median age
of 27 (range, 22–66), and the healthy controls had a me-
dian age of 25 (range, 20–33). Bacille Calmette-Guérin
(BCG) scars were present in 65.2% of patients with ac-
tive TB and 57.1% of healthy controls during inspection
at the site. None of the enrolled patients were acid-fast
bacillus smear-positive, 19 (82.6%) were culture-positive,
and 8 (34.8%) had a cavity on a chest X-ray or computed
tomography (CT) (Table 1).
Comparison of serum and urine IP-10 levels between
healthy controls and patients with TB at diagnosis
We assessed whether the levels of IP-10 in serum and
urine samples differed between TB patients at the time
of diagnosis and healthy controls. Serum IP-10 levels did
not differ significantly between TB patients at diagnosis
(median, 85.37 pg/ml; IQR, 60.92-171.30) and healthy
controls (median, 68.62 pg/ml; IQR, 43.19-87.01), al-
though the levels in patients were slightly higher than
those in the healthy controls (P = 0.0829; Fig. 1a). In
addition, urine IP-10 levels in healthy controls (median,
6.49 pg/ml; IQR, 2.02-12.11) were not different from
those in the TB patients at the time of diagnosis (me-
dian, 7.89 pg/ml; IQR, 4.86-13.97; Fig. 1b).
Comparison of serum and urine IP-10 levels at TB
diagnosis (T0), during treatment (T2), and after the
completion of therapy (T6)
We further analysed whether the serum and urine IP-
10 levels in TB patients changed over the course of
treatment with a complete set of serial specimens
(T0, T2, and T6). Serum IP-10 levels in TB patients
at the time of diagnosis (median, 85.37 pg/ml; IQR,
60.92-171.30) were not significantly different from
those after 2 months of treatment (median, 125.
80 pg/ml; IQR, 81.42-155.00; P = 0.1743) or upon the
completion of effective therapy (median, 81.09 pg/ml;
IQR, 63.71-123.70; P = 0.7467; Fig. 2a).
However, the pairwise comparisons also showed that
urine IP-10 levels in patients after 2 months of treat-
ment (median, 19.17 pg/ml; IQR, 5.12-51.68) were sig-
nificantly higher than those in patients at the time of
diagnosis (median, 7.89 pg/ml; IQR, 4.86-13.97; P = 0.
0163). Moreover, urine IP-10 levels in patients tested
after the completion of drug therapy (median, 5.47 pg/
ml; IQR, 4.69-9.79) were significantly lower than those





Median Age (range) 27 (22–66) 25 (20–33)
Male, n (%) 16 (59.3%) 13 (62.0%)
Presence of BCGa scars 15 (65.2%) 12 (57.1%)
PTBb diagnosis AFBc smear, positive 0 (0.0%) 0 (0.0%)
AFBc culture, positive 19 (82.6%) 0 (0.0%)
Cavity on Chest X-ray or CTd 8 (34.8%) 0 (0.0%)
Risk group for relapse High-risk 0 (0.0%) 0 (0.0%)
Moderate-risk 8 (34.8%) 0 (0.0%)
Low-risk 15 (65.2%) 0 (0.0%)
aBCG Bacille Calmette-Guérin, b PTB Pulmonary tuberculosis, c AFB Acid-fast bacillus; d CT Computed tomography. Risk factors for relapse: i) the presence of a
cavity lesion on chest X-ray or chest CT, and ii) the result of a positive sputum culture after 2 months of anti-TB treatment. The high-risk group was defined when
patients had both risk factors i) and ii). The moderate-risk group was defined when patients had either risk factor i) or ii), and the low-risk group had neither
risk factor
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sampled at the time of diagnosis (P = 0.0354) and after
2 months of treatment (P = 0.0035; Fig. 2b).
To confirm that the IP-10 response derived from TB
infection, the urine IP-10 level of each patient was nor-
malized to the serum creatinine level at each visit using
test results available from routine analyses. As an abnor-
mal serum creatinine level may indicate kidney disease
or damage, this served to verify that the dynamics of IP-
10 levels detected in this study were not influenced by
kidney disease. The urine IP-10/creatinine ratio was
higher in TB patients after 2 months of treatment than
either before or after treatment, consistent with the
trend observed for urine IP-10 without normalization
(Fig. 2c). This indicated that the serum creatinine levels
did not affect the urine IP-10 levels in this study.
Longitudinal analysis of IP-10 levels in patients with
active TB stratified by risk group
The group of TB patients was then sub-divided by risk
factors for relapse or treatment failure into low, moder-
ate, and high-risk groups. Among all patients, 15 (65.2%)
were included in the low-risk group, and 8 (34.8%) were
included in the moderate/high-risk group.
As shown in Fig. 3b and c, the smoothed lines for
urine IP-10 in both risk groups exhibited a similar trend
over the three time points. The low-risk group had
higher urine IP-10 levels than those of the moderate/
high-risk group, but the 95% confidence limits of IP-10
levels were not differentiated by risk group.
In contrast, serum IP-10 levels did not show similar
trends in the two risk groups (Fig. 3a). Serum IP-10
Fig. 1 Serum and urine IP-10 levels in patients with TB at diagnosis and healthy controls. IP-10 levels were measured in the serum (a) and urine
(b) of each TB patient at diagnosis (T0) and each healthy control (HC). We only obtained serum samples from 17 patients at T0 out of 23 patients.
The data are shown as median with interquartile range; statistical analyses were performed using the Mann–Whitney U-test
Fig. 2 Serum and urine IP-10 levels in patients with TB before, during, and after treatment. Serial IP-10 levels in the (a) serum and (b) urine of
patients with TB collected at the time of diagnosis (T0), after 2 months of therapy (T2), and after the completion of therapy (T6). c Serial IP-10
levels in urine normalized against serum creatinine levels in patients. The data are shown as median with interquartile range; statistical analyses
were performed using the Wilcoxon matched-pairs signed rank test
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levels in the moderate/high-risk group did not change
over time, but those in the low-risk group increased at
T2 and decreased at T6, similar to the results for urine
IP-10 levels.
Discussion
As sputum culture conversion at 2 months is not always
predictive of successful TB therapy, new biomarkers for
predicting treatment responses are needed for better man-
agement of TB patients. Similar to the findings of Cannas
et al. [20], this study showed a declining tendency for urine
IP-10 detection in TB patients after receiving effective anti-
TB drug therapy compared the levels at time of diagnosis.
However, this study also detected urine IP-10 levels after
2 months of an intensive anti-TB drug therapy, which is the
point when clinicians routinely use radiological and bac-
teriological tests to determine treatment progress. Although
recent studies have reported a decline in blood IP-10 levels
after 2 weeks of efficient anti-TB drug therapy as an early
biomarker for treatment response [21, 22], this study dem-
onstrated a peak in urine IP-10 levels after 2 months of
treatment in HIV-negative patients with tuberculosis.
Moreover, the same trend was observed in patients regard-
less of risk factors for TB relapse or treatment failure.
It is not clear why unstimulated IP-10 levels in urine
significantly increase in patients after 2 months of anti-
TB treatment. A previous study using imaging scans
suggested quantitative changes at 2 months after the
initiation of treatment, which may be related to long-
term TB treatment outcome [23]. To confirm this
phenomenon, additional investigations with a large-scale
active TB cases including prolonged anti-TB treatment
(over 12 months) may be useful to ensure the timing of
peak inflammation and urine IP-10 for successful
treatment.
Individuals with acute and chronic infections were ex-
cluded from analyses, and urine IP-10 levels were nor-
malized against serum creatinine levels to ensure that
increases in urine IP-10 levels can be attributed to infec-
tion with M. tuberculosis, rather than kidney disease or
damage. In future studies, urine creatinine levels should
be examined to directly exclude urinary disease.
In addition, C-reactive protein (CRP) is an indicator of
disease activity and is often increased in active tubercu-
losis inflammatory conditions [24, 25]. However, CRP
data for patients at diagnosis and follow-ups were not
available in this study. In future studies, CRP levels
should be estimated and their correlations with IP-10
levels can be used to assess inflammatory changes in re-
sponse to TB treatment. Furthermore, this study empha-
sizes the usefulness of urine as non-invasive sample for
monitoring treatment responses biomarkers in children,
the elderly and HIV-infected subjects.
Conclusions
In conclusion, unstimulated IP-10 levels in patient urine
samples, which are easier to collect and analyse than blood
samples, can be used as a predictive factor, indicating a
positive treatment response. IP-10 detection may therefore
be a useful monitoring tool for determining whether TB pa-
tients are positively responding to anti-TB drug therapy.
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